KRMD News

KORU Medical Systems Announces Q2 2025 Financial Results, Including Record Double-digit Revenue, and Raises 2025 Revenue Guidance

KRMD

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Highlights •   Second quarter 2025 net revenues of $10.2 million, a 21% increase over the prior year period       •   Core bus

August 6, 2025Earnings
Read more →

KORU Medical Systems To Join Russell 3000 And Russell 2000 Indexes

KRMD

June 11, 2025
Read more →

KORU Medical Systems to Join Russell 3000® and Russell 2000® Indexes

KRMD

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US

Piper Sandler Maintains Neutral on KORU Medical Systems, Lowers Price Target to $3.5

KRMD

May 8, 2025
Read more →

KORU Medical Systems Raises FY2025 Sales Guidance from $38.00M-$39.00M to $38.50M-$39.50M vs $38.43M Est

KRMD

May 7, 2025
Read more →

KORU Medical Systems Q1 Sales $9.63M Beat $8.87M Estimate

KRMD

May 7, 2025
Read more →

KORU Medical Systems Q4 2024 Adj. EPS $(0.02) Beats $(0.03) Estimate, Sales $8.839M Miss $8.893M Estimate

KRMD

March 12, 2025
Read more →

Piper Sandler Downgrades KORU Medical Systems to Neutral, Maintains Price Target to $4.5

KRMD

February 14, 2025
Read more →

Lake Street Maintains Buy on KORU Medical Systems, Raises Price Target to $5

KRMD

January 14, 2025
Read more →

KORU Medical Systems Announces Preliminary Q4 Net Revenues Of $8.9M, 23% Growth; Sees FY24 Revenues At $33.7M, Up 18%; Cash Balance At $9.6M, Q4 Cash Flow Of $0.8M, Yearly Cash Burn Improved by 67%

KRMD

January 13, 2025
Read more →

Craig-Hallum Maintains Buy on KORU Medical Systems, Raises Price Target to $5

KRMD

November 14, 2024
Read more →

Canaccord Genuity Maintains Buy on KORU Medical Systems, Raises Price Target to $4

KRMD

November 14, 2024
Read more →

Piper Sandler Maintains Overweight on KORU Medical Systems, Raises Price Target to $3.5

KRMD

November 14, 2024
Read more →

KORU Medical Systems Presents Data Demonstrating Nursing Preference For Use Of KORU FreedomEdge Infusion System Over Manual Syringe Administration For Subcutaneous Oncology Infusion At Partnership Opportunities In Drug Delivery Conference

KRMD

October 31, 2024
Read more →

KORU Medical Systems Receives FDA 510(k) Clearance For Delivery Of EMPAVELI, Expands European Label For FreedomEdge

KRMD

May 2, 2022
Read more →